Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127112) titled 'Real-world treatment status in patients with anaplastic lymphoma kinase (ALK)-positive initial unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC): An observational clinical study' on June 24.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Affiliated Hospital of Guangdong Medical University
Condition:
ALK-positive initial unresectable locally advanced or metastatic NSCLC
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-07-31
Target Sample Size: Observation group:47;
Countries of Recruitment:
China
To know more, visit htt...